Adakveo Adakveo

Generic name:

CRIZANLIZUMAB-TMCA

Company:

NOVARTIS PHARMS CORP

FDA approval date:

11/15/2019

Specific treatment:

ADAKVEO is a selectin blocker indicated to reduce the frequency of
vasoocclusive crises in adults and pediatric patients aged 16 years and older
with sickle cell disease

Mechanism of Action:

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with
its ligands including P-selectin glycoprotein ligand 1.
Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells,
platelets, red blood cells, and leukocytes. 

Dosage Form/Route:

Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial. 

Side Effects:

Most common adverse reactions (incidence > 10%) are nausea, arthralgia,
back pain, and pyrexia.